## Carmen Adduci

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4408770/publications.pdf

Version: 2024-02-01

1039406 940134 23 288 9 16 citations h-index g-index papers 23 23 23 436 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	A mobile app for improving the compliance with remote management of patients with cardiac implantable devices: a multicenter evaluation in clinical practice. Journal of Interventional Cardiac Electrophysiology, 2022, 64, 257-264.	0.6	4
2	Multi-Modality Imaging Approach in a Challenging Case of Surgically Corrected Partial Anomalous Pulmonary Venous Return and Atrial Tachycardia Treated With Radiofrequency Ablation. Cureus, 2021, 13, e13009.	0.2	1
3	Left Ventricular Remodeling in Hypertrophic Cardiomyopathy: An Overview of Current Knowledge. Journal of Clinical Medicine, 2021, 10, 1547.	1.0	11
4	Acute shock efficacy of the subcutaneous implantable cardioverterâ€defibrillator according to the implantation technique. Journal of Cardiovascular Electrophysiology, 2021, 32, 1695-1703.	0.8	8
5	Home delivery of the communicator for remote monitoring of cardiac implantable devices: A multicenter experience during the covidâ€19 lockdown. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 995-1003.	0.5	13
6	Novel Imaging and Genetic Risk Markers in Takotsubo Syndrome. Frontiers in Cardiovascular Medicine, 2021, 8, 703418.	1.1	8
7	Implantation technique and optimal subcutaneous defibrillator chest position: a PRAETORIAN score-based study. Europace, 2020, 22, 1822-1829.	0.7	31
8	Prognostic implications of nonsustained ventricular tachycardia morphology in highâ€risk patients with hypertrophic cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2020, 31, 2093-2098.	0.8	5
9	Prevention of Sudden Cardiac Death: Focus on the Subcutaneous Implantable Cardioverter-Defibrillator. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 291-297.	1.0	O
10	Assessing Atrial Fibrillation Substrates by P Wave Analysis: A Comprehensive Review. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 341-347.	1.0	6
11	Ventricular fibrillation undersensing due to air entrapment in a patient implanted with a subcutaneous cardioverter defibrillator. Journal of Cardiovascular Electrophysiology, 2019, 30, 1373-1374.	0.8	5
12	The subcutaneous implantable cardioverter-defibrillator: Current trends in clinical practice between guidelines and technology progress. European Journal of Internal Medicine, 2019, 65, 6-11.	1.0	3
13	Safety and efficacy of antiâ€ŧachycardia pacing in patients with hypertrophic cardiomyopathy implanted with an ICD. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 610-616.	0.5	10
14	Subcutaneous implantable cardioverter defibrillator eligibility according to a novel automated screening tool and agreement with the standard manual electrocardiographic morphology tool. Journal of Interventional Cardiac Electrophysiology, 2018, 52, 61-67.	0.6	27
15	Autonomic cardiovascular control and cardiac arrhythmia in two pregnant women with hypertrophic cardiomyopathy: Insights from ICD monitoring. Revista Portuguesa De Cardiologia, 2018, 37, 351.e1-351.e4.	0.2	2
16	Long-Term Left Ventricular Remodeling of Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2018, 122, 1924-1931.	0.7	15
17	Safety, Efficacy and Evidence Base for Use of the Subcutaneous Implantable Cardioverter Defibrillator. Journal of Clinical Medicine, 2018, 7, 53.	1.0	11
18	Pulmonary hypertension and clinical correlates in hypertrophic cardiomyopathy. International Journal of Cardiology, 2017, 248, 326-332.	0.8	28

#	Article	IF	CITATIONS
19	Prognostic Implications of Defibrillation Threshold Testing in Patients With Hypertrophic Cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2017, 28, 103-108.	0.8	18
20	Eligibility for the Subcutaneous Implantable Cardioverterâ€Defibrillator in Patients With Hypertrophic Cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2015, 26, 893-899.	0.8	45
21	RyR2 Common Gene Variant G1886S and the Risk of Ventricular Arrhythmias in ICD Patients with Heart Failure. Journal of Cardiovascular Electrophysiology, 2015, 26, 656-661.	0.8	4
22	Angiotensin Receptor Antagonists to Prevent Sudden Death in Heart Failure: Does the Dose Matter?. ISRN Cardiology, 2014, 2014, 1-7.	1.6	7
23	Clinical Impact of Nonsustained Ventricular Tachycardia Recorded by the Implantable Cardioverterâ€Defibrillator in Patients with Hypertrophic Cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2014, 25, 1180-1187.	0.8	26